TABLE 2.
Clinical trials using CAR T-cells for the treatment of melanoma and other solid tumors.
| Title | Target Antigen | Cancer | Status | ClinicalTrials.gov Identifier |
|---|---|---|---|---|
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | CAR-T/TCR-T cells multi-target including CD19, CD22, CD33, BCMA, CD38, NY-ESO-1, DR5, C-met, EGFR V III, Mesothelin | B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma, Hepatoma, Gastric Cancer, Pancreatic Cancer, Mesothelioma, Colorectal Cancer, Esophagus Cancer, Lung Cancer, Glioma, Melanoma, Synovial Sarcoma, Ovarian Cancer, Renal Carcinoma | Recruiting | NCT03638206 |
| B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | B7H3 | Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma, Wilms Tumor, Rhabdoid Tumor, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, Clear Cell Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Desmoplastic Small Round Cell Tumor, Soft Tissue Sarcoma, Neuroblastoma, Melanoma | Recruiting | NCT04483778 |
| Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma | IL13Ralpha2 | Stage IIIC or IV Melanoma | Recruiting | NCT04119024 |
| MB-CART20.1 Melanoma | CD20 | Melanoma (Skin) | Unknown | NCT03893019 |
| CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | VEGFR2 | Metastatic Melanoma | Terminated | NCT01218867 |
| Renal Cancer | ||||
| A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors | GD2 | melanoma, sarcoma, osteosarcoma, neuroblastoma | Completed | NCT02107963 |
| Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | CD70 | Melanoma, Pancreatic, Renal, Ovarian and Breast Cancer | Suspended | NCT02830724 |
| B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3 CAR) | B7-H3 | Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma, Ewing Sarcoma, Wilms Tumor, Adrenocortical Cancer, Desmoplastic Small Round Cell Tumor, Germ Cell Cancer, Rhabdoid Tumor, Clear Cell Sarcoma, Hepatoblastoma, Melanoma, Carcinoma, Malignant Peripheral Nerve Sheath Tumors, Soft Tissue Sarcoma | Not yet recruiting | NCT04897321 |
| Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy | GPA-TriMAR | Melanoma | Recruiting | NCT03649529 |
| C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | C7R-GD2 | Neuroblastoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Uveal Melanoma, Phyllodes Breast Tumor | Recruiting | NCT03635632 |
| Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET) | MET scFv | Malignant Melanoma, Breast Cancer | Terminated | NCT03060356 |